RIPK1 and cancer: Thus, the RIPK1-NF-κB signalling axis promotes immunosuppression in surviving cancer cells, whereas decoupling of dual RIPK1 signalling in dying cancer cells can trigger the immune microenvironment to transit from suppression to activation, mediating increased ICD in cancer cells.